199 related articles for article (PubMed ID: 29336998)
1. Developing a Predictive Model for Clinical Outcomes of Advanced Non-Small Cell Lung Cancer Patients Treated With Nivolumab.
Park W; Kwon D; Saravia D; Desai A; Vargas F; El Dinali M; Warsch J; Elias R; Chae YK; Kim DW; Warsch S; Ishkanian A; Ikpeazu C; Mudad R; Lopes G; Jahanzeb M
Clin Lung Cancer; 2018 May; 19(3):280-288.e4. PubMed ID: 29336998
[TBL] [Abstract][Full Text] [Related]
2. Pretreatment advanced lung cancer inflammation index (ALI) for predicting early progression in nivolumab-treated patients with advanced non-small cell lung cancer.
Shiroyama T; Suzuki H; Tamiya M; Tamiya A; Tanaka A; Okamoto N; Nakahama K; Taniguchi Y; Isa SI; Inoue T; Imamura F; Atagi S; Hirashima T
Cancer Med; 2018 Jan; 7(1):13-20. PubMed ID: 29150906
[TBL] [Abstract][Full Text] [Related]
3. Neutrophil-to-lymphocyte ratio evolution is an independent predictor of early progression of second-line nivolumab-treated patients with advanced non-small-cell lung cancers.
Dusselier M; Deluche E; Delacourt N; Ballouhey J; Egenod T; Melloni B; Vergnenègre C; Veillon R; Vergnenègre A
PLoS One; 2019; 14(7):e0219060. PubMed ID: 31314761
[TBL] [Abstract][Full Text] [Related]
4. Role of antibiotic use, plasma citrulline and blood microbiome in advanced non-small cell lung cancer patients treated with nivolumab.
Ouaknine Krief J; Helly de Tauriers P; Dumenil C; Neveux N; Dumoulin J; Giraud V; Labrune S; Tisserand J; Julie C; Emile JF; Chinet T; Giroux Leprieur E
J Immunother Cancer; 2019 Jul; 7(1):176. PubMed ID: 31292005
[TBL] [Abstract][Full Text] [Related]
5. Comparable outcomes of nivolumab in patients with advanced NSCLC presenting with or without brain metastases: a retrospective cohort study.
Zhang G; Cheng R; Wang H; Zhang Y; Yan X; Li P; Zhang M; Zhang X; Yang J; Niu Y; Ma Z
Cancer Immunol Immunother; 2020 Mar; 69(3):399-405. PubMed ID: 31907567
[TBL] [Abstract][Full Text] [Related]
6. Serum PCSK9 levels at the second nivolumab cycle predict overall survival in elderly patients with NSCLC: a pilot study.
Bonaventura A; Grossi F; Carbone F; Vecchié A; Minetti S; Bardi N; Elia E; Ansaldo AM; Ferrara D; Rijavec E; Dal Bello MG; Rossi G; Biello F; Tagliamento M; Alama A; Coco S; Spallarossa P; Dallegri F; Genova C; Montecucco F
Cancer Immunol Immunother; 2019 Aug; 68(8):1351-1358. PubMed ID: 31327024
[TBL] [Abstract][Full Text] [Related]
7. Longitudinal Tumor Size and Neutrophil-to-Lymphocyte Ratio Are Prognostic Biomarkers for Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Durvalumab.
Gavrilov S; Zhudenkov K; Helmlinger G; Dunyak J; Peskov K; Aksenov S
CPT Pharmacometrics Syst Pharmacol; 2021 Jan; 10(1):67-74. PubMed ID: 33319498
[TBL] [Abstract][Full Text] [Related]
8. The relationship between clinicopathological variables, systemic inflammation, and CT-derived body composition with survival in patients with advanced non-small cell lung cancer receiving nivolumab as a second-line treatment.
Saeed R; McGovern J; Bench H; Dolan RD; McMillan DC; Cascales A
Cancer Med; 2023 Dec; 12(24):22062-22070. PubMed ID: 38088761
[TBL] [Abstract][Full Text] [Related]
9. Opioids impair nivolumab outcomes: a retrospective propensity score analysis in non-small-cell lung cancer.
Taniguchi Y; Tamiya A; Matsuda Y; Adachi Y; Enomoto T; Azuma K; Kouno S; Tokoro A; Atagi S
BMJ Support Palliat Care; 2023 Oct; 13(e1):e185-e189. PubMed ID: 33293293
[TBL] [Abstract][Full Text] [Related]
10. Association between antibiotics use and outcome in patients with NSCLC treated with immunotherapeutics.
Huemer F; Rinnerthaler G; Lang D; Hackl H; Lamprecht B; Greil R
Ann Oncol; 2019 Apr; 30(4):652-653. PubMed ID: 30689705
[No Abstract] [Full Text] [Related]
11. Considerations for the Cure Assumption in an NICE Single Technology Appraisal of Nivolumab with Chemotherapy for Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer: Evidence Assessment Group Perspective.
Orozco-Leal G; Johnson EE; Hosseinijebeli S; Robinson T; Homer T; Eastaugh CH; Richmond C; Tanner L; Meader N; Kenny R; Wallace SA; Rice S
Pharmacoeconomics; 2024 Feb; 42(2):133-136. PubMed ID: 37985576
[No Abstract] [Full Text] [Related]
12. Combining Classic and Novel Neutrophil-Related Biomarkers to Identify Non-Small-Cell Lung Cancer.
Ren Y; Wang Q; Xu C; Guo Q; Dai R; Xu X; Zhang Y; Wu M; Wu X; Tu H
Cancers (Basel); 2024 Jan; 16(3):. PubMed ID: 38339264
[TBL] [Abstract][Full Text] [Related]
13. Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients.
Garde-Noguera J; Martin-Martorell P; De Julián M; Perez-Altozano J; Salvador-Coloma C; García-Sanchez J; Insa-Molla A; Martín M; Mielgo-Rubio X; Marin-Liebana S; Blasco-Cordellat A; Blasco-Molla S; Gironés R; Marquez-Medina D; Aparisi F; Cerda MCB; Macia-Escalante S; Sánchez A; Juan-Vidal O
Clin Transl Oncol; 2018 Aug; 20(8):1072-1079. PubMed ID: 29368144
[TBL] [Abstract][Full Text] [Related]
14. Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing.
Rizvi H; Sanchez-Vega F; La K; Chatila W; Jonsson P; Halpenny D; Plodkowski A; Long N; Sauter JL; Rekhtman N; Hollmann T; Schalper KA; Gainor JF; Shen R; Ni A; Arbour KC; Merghoub T; Wolchok J; Snyder A; Chaft JE; Kris MG; Rudin CM; Socci ND; Berger MF; Taylor BS; Zehir A; Solit DB; Arcila ME; Ladanyi M; Riely GJ; Schultz N; Hellmann MD
J Clin Oncol; 2018 Mar; 36(7):633-641. PubMed ID: 29337640
[TBL] [Abstract][Full Text] [Related]
15. Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy.
Hodi FS; Ballinger M; Lyons B; Soria JC; Nishino M; Tabernero J; Powles T; Smith D; Hoos A; McKenna C; Beyer U; Rhee I; Fine G; Winslow N; Chen DS; Wolchok JD
J Clin Oncol; 2018 Mar; 36(9):850-858. PubMed ID: 29341833
[TBL] [Abstract][Full Text] [Related]
16. Combining chemotherapy with PD-1 blockade in NSCLC.
Mathew M; Enzler T; Shu CA; Rizvi NA
Pharmacol Ther; 2018 Jun; 186():130-137. PubMed ID: 29352857
[TBL] [Abstract][Full Text] [Related]
17. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases.
Vokes EE; Ready N; Felip E; Horn L; Burgio MA; Antonia SJ; Arén Frontera O; Gettinger S; Holgado E; Spigel D; Waterhouse D; Domine M; Garassino M; Chow LQM; Blumenschein G; Barlesi F; Coudert B; Gainor J; Arrieta O; Brahmer J; Butts C; Steins M; Geese WJ; Li A; Healey D; Crinò L
Ann Oncol; 2018 Apr; 29(4):959-965. PubMed ID: 29408986
[TBL] [Abstract][Full Text] [Related]
18. Rheumatic manifestations among cancer patients treated with immune checkpoint inhibitors.
Lidar M; Giat E; Garelick D; Horowitz Y; Amital H; Steinberg-Silman Y; Schachter J; Shapira-Frommer R; Markel G
Autoimmun Rev; 2018 Mar; 17(3):284-289. PubMed ID: 29341936
[TBL] [Abstract][Full Text] [Related]
19. Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer.
Ilié M; Szafer-Glusman E; Hofman V; Chamorey E; Lalvée S; Selva E; Leroy S; Marquette CH; Kowanetz M; Hedge P; Punnoose E; Hofman P
Ann Oncol; 2018 Jan; 29(1):193-199. PubMed ID: 29361135
[TBL] [Abstract][Full Text] [Related]
20. Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression.
Lin H; Wei S; Hurt EM; Green MD; Zhao L; Vatan L; Szeliga W; Herbst R; Harms PW; Fecher LA; Vats P; Chinnaiyan AM; Lao CD; Lawrence TS; Wicha M; Hamanishi J; Mandai M; Kryczek I; Zou W
J Clin Invest; 2018 Feb; 128(2):805-815. PubMed ID: 29337305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
